Format

Send to

Choose Destination
Nat Med. 2018 Dec;24(12):1859-1866. doi: 10.1038/s41591-018-0233-1. Epub 2018 Nov 12.

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.

Author information

1
Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA.
2
Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
3
Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, CO, USA.
4
RNA Bioscience Initiative, University of Colorado School of Medicine, Aurora, CO, USA.
5
Department of Biostatistics and Informatics, University of Colorado School of Medicine, Aurora, CO, USA.
6
Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA. Craig.jordan@ucdenver.edu.

Abstract

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Leukemia stem cells (LSCs) drive the initiation and perpetuation of AML, are quantifiably associated with worse clinical outcomes, and often persist after conventional chemotherapy resulting in relapse1-5. In this report, we show that treatment of older patients with AML with the B cell lymphoma 2 (BCL-2) inhibitor venetoclax in combination with azacitidine results in deep and durable remissions and is superior to conventional treatments. We hypothesized that these promising clinical results were due to targeting LSCs. Analysis of LSCs from patients undergoing treatment with venetoclax + azacitidine showed disruption of the tricarboxylic acid (TCA) cycle manifested by decreased α-ketoglutarate and increased succinate levels, suggesting inhibition of electron transport chain complex II. In vitro modeling confirmed inhibition of complex II via reduced glutathionylation of succinate dehydrogenase. These metabolic perturbations suppress oxidative phosphorylation (OXPHOS), which efficiently and selectively targets LSCs. Our findings show for the first time that a therapeutic intervention can eradicate LSCs in patients with AML by disrupting the metabolic machinery driving energy metabolism, resulting in promising clinical activity in a patient population with historically poor outcomes.

PMID:
30420752
DOI:
10.1038/s41591-018-0233-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center